HRP20220446T1 - Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma) - Google Patents
Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma) Download PDFInfo
- Publication number
- HRP20220446T1 HRP20220446T1 HRP20220446TT HRP20220446T HRP20220446T1 HR P20220446 T1 HRP20220446 T1 HR P20220446T1 HR P20220446T T HRP20220446T T HR P20220446TT HR P20220446 T HRP20220446 T HR P20220446T HR P20220446 T1 HRP20220446 T1 HR P20220446T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- cr5r6
- formula
- disease
- image
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- -1 pivaloyloxymethyl Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4084—Esters with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4087—Esters with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4465—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Spoj formule (I) ili formule (II):
[image]
[image]
pri čemu: svaki R1, R3, i R4 je izabran od sljedećih: pivaloiloksimetil (POM) i izopropiloksikarboniloksimetil (POC), tako da ili oba R3, i R4 su svaki pivaloiloksimetil (POM), ili oba R3, i R4 su svaki izopropiloksikarboniloksimetil (POC), i
svaki R2, je neovisno izabran iz grupe koja se sastoji od sljedećih: H, alkil, Ar, -(CR5R6)n-Ar, -(CR5R6)n-O-C(=O)-R7, -(CR5R6)n-C(=O)-O-R7, -(CR5R6)n-O-C(=O)-O-R7,-(CR5R6)n-O-R7, -(CR5R6)n-O-[(CR5R6)n-O]m-R7, -(CR5R6)n-Ar-O-C(=O)-R7, -Ar-C(=O)-O-(CR5R6)n-R7, -(CR5R6)n-NR8R9, i -(CR5R6)n-C(=O)-NR8R9;
gdje:
n je cijeli broj od 1 do 20;
m je cijeli broj od 1 do 20;
svaki R3' i R4' su neovisno H ili alkil;
svaki R5 i R6 je neovisno izabran iz grupe koja se sastoji od sljedećih: H, alkil i alkilaril;
svaki R7 je neovisno ravan ili razgranati alkil;
Ar je aril, supstituirani aril, heteroaril ili supstituirani heteroaril; i
R8 i R9 su svaki neovisno H ili alkil; i
njihove farmaceutski prihvatljive soli.
2. Spoj prema zahtjevu 1, naznačen time što je spoj formule (I) izabran iz grupe koja se sastoji od:
[image]
i
[image]
3. Spoj prema zahtjevu 1, naznačen time što spoj formule (I) je
[image]
4. Spoj prema zahtjevu 1, naznačen time što spoj formule (I) je
[image]
5. Spoj prema zahtjevu 1, naznačen time što spoj formule (I) je
[image]
6. Spoj sljedeće formule
[image]
7. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od zahtjeva 1-6 i farmaceutski prihvatljiv ekscipijens.
8. Spoj ili kompozicija prema bilo kojem od zahtjeva 1-7 za uporabu u liječenju bolesti ili stanja.
9. Spoj ili kompozicija za uporabu prema zahtjevu 8, naznačen time što je bolest ili stanje izabrano iz grupe koja se sastoji od sljedećih: neurodegenerativna bolest, multipla skleroza (MS), rak, angiogeneza i upalna bolest crijeva.
10. Spoj ili kompozicija za uporabu prema zahtjevu 9, naznačen time što je neurodegenerativna bolest izabrana iz grupe koja se sastoji od sljedećih: amiotrofna lateralna skleroza (ALS), Parkinsonova bolest (PD), Alzheimerova bolest (AD), Huntingtonova bolest, demencija sa Lewyjevim tijelima (DLB), shizofrenija, bol, epilepsija, moždani udar i traumatska povreda mozga (TBI).
11. Spoj ili kompozicija za uporabu prema zahtjevu 8, naznačen time što bolest ili stanje rezultira viškom aktivnosti PSMA.
12. Spoj ili kompozicija za uporabu prema zahtjevu 11, naznačen time što je višak aktivnosti PSMA inhibiran kada se primjenjuje spoj formule (I), spoj formule (II) ili njegova farmaceutska kompozicija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033926P | 2014-08-06 | 2014-08-06 | |
| EP15829215.1A EP3177632B1 (en) | 2014-08-06 | 2015-08-06 | Prodrugs of prostate specific membrane antigen (psma) inhibitor |
| PCT/US2015/044053 WO2016022827A1 (en) | 2014-08-06 | 2015-08-06 | Prodrugs of prostate specific membrane antigen (psma) inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220446T1 true HRP20220446T1 (hr) | 2022-05-27 |
Family
ID=55264571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220446TT HRP20220446T1 (hr) | 2014-08-06 | 2015-08-06 | Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma) |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9988407B2 (hr) |
| EP (1) | EP3177632B1 (hr) |
| CA (1) | CA2961880C (hr) |
| CY (1) | CY1125201T1 (hr) |
| DK (1) | DK3177632T3 (hr) |
| ES (1) | ES2908411T3 (hr) |
| HR (1) | HRP20220446T1 (hr) |
| HU (1) | HUE058072T2 (hr) |
| LT (1) | LT3177632T (hr) |
| PL (1) | PL3177632T3 (hr) |
| PT (1) | PT3177632T (hr) |
| RS (1) | RS63082B1 (hr) |
| SI (1) | SI3177632T1 (hr) |
| WO (1) | WO2016022827A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4374924A2 (en) | 2013-10-18 | 2024-05-29 | Novartis AG | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US10172873B2 (en) * | 2014-08-06 | 2019-01-08 | The Johns Hopkins University | Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors |
| LT3177632T (lt) | 2014-08-06 | 2022-04-25 | The Johns Hopkins University | Prostatos specifinio membraninio antigeno (psma) inhibitoriaus provaistai |
| JP2020530007A (ja) * | 2017-04-11 | 2020-10-15 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｐｓｍａ標的化ガンイメージングまたは放射線療法中の健康組織保護のための２−ｐｍｐａのプロドラッグ |
| GB201810965D0 (en) * | 2018-07-04 | 2018-08-15 | Univ College Cardiff Consultants Ltd | Phosphoantigen prodrug compounds |
| WO2020030954A1 (en) | 2018-08-09 | 2020-02-13 | Integrative Medicine Clinic, Sia | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
| US20210323985A1 (en) * | 2018-09-21 | 2021-10-21 | Endocyte, Inc. | Shielding agents and their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| DE60238435D1 (de) | 2001-10-26 | 2011-01-05 | Scripps Research Inst | Gezielte thrombose durch gewebefaktor polypeptiden |
| US20060046978A1 (en) | 2004-08-31 | 2006-03-02 | Morphochem Ag | Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE) |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| US10172873B2 (en) * | 2014-08-06 | 2019-01-08 | The Johns Hopkins University | Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors |
| LT3177632T (lt) * | 2014-08-06 | 2022-04-25 | The Johns Hopkins University | Prostatos specifinio membraninio antigeno (psma) inhibitoriaus provaistai |
-
2015
- 2015-08-06 LT LTEPPCT/US2015/044053T patent/LT3177632T/lt unknown
- 2015-08-06 ES ES15829215T patent/ES2908411T3/es active Active
- 2015-08-06 HR HRP20220446TT patent/HRP20220446T1/hr unknown
- 2015-08-06 SI SI201531827T patent/SI3177632T1/sl unknown
- 2015-08-06 PT PT158292151T patent/PT3177632T/pt unknown
- 2015-08-06 DK DK15829215.1T patent/DK3177632T3/da active
- 2015-08-06 CA CA2961880A patent/CA2961880C/en active Active
- 2015-08-06 WO PCT/US2015/044053 patent/WO2016022827A1/en active Application Filing
- 2015-08-06 US US15/502,105 patent/US9988407B2/en active Active
- 2015-08-06 HU HUE15829215A patent/HUE058072T2/hu unknown
- 2015-08-06 EP EP15829215.1A patent/EP3177632B1/en active Active
- 2015-08-06 PL PL15829215T patent/PL3177632T3/pl unknown
- 2015-08-06 RS RS20220332A patent/RS63082B1/sr unknown
-
2018
- 2018-05-01 US US15/968,074 patent/US10544176B2/en active Active
-
2020
- 2020-01-24 US US16/751,556 patent/US11325931B2/en active Active
-
2022
- 2022-04-04 CY CY20221100255T patent/CY1125201T1/el unknown
- 2022-05-09 US US17/739,669 patent/US11932664B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| LT3177632T (lt) | 2022-04-25 |
| US11932664B2 (en) | 2024-03-19 |
| CY1125201T1 (el) | 2024-02-16 |
| US20200399298A1 (en) | 2020-12-24 |
| HUE058072T2 (hu) | 2022-07-28 |
| CA2961880A1 (en) | 2016-02-11 |
| US20170226141A1 (en) | 2017-08-10 |
| EP3177632A4 (en) | 2018-04-04 |
| ES2908411T3 (es) | 2022-04-29 |
| US10544176B2 (en) | 2020-01-28 |
| US20230115651A1 (en) | 2023-04-13 |
| DK3177632T3 (da) | 2022-03-21 |
| US20180244705A1 (en) | 2018-08-30 |
| PT3177632T (pt) | 2022-03-21 |
| RS63082B1 (sr) | 2022-04-29 |
| CA2961880C (en) | 2022-09-27 |
| PL3177632T3 (pl) | 2022-06-13 |
| US11325931B2 (en) | 2022-05-10 |
| WO2016022827A1 (en) | 2016-02-11 |
| SI3177632T1 (sl) | 2022-05-31 |
| US9988407B2 (en) | 2018-06-05 |
| EP3177632B1 (en) | 2022-01-12 |
| EP3177632A1 (en) | 2017-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220446T1 (hr) | Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma) | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| HRP20191414T1 (hr) | Novi spojevi i derivati spiro[3h-indol-3,2'-pirolidin]-2(1h)-ona kao mdm1-p53-inhibitori | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| PH12014502173B1 (en) | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| BR112015013450A8 (pt) | compostos bicíclicos, uso dos compostos, composição farmacêutica, complexo molecular e processo para preparação dos referidos compostos | |
| PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| BR112017000943A2 (pt) | ácidos carboxílicos heterocíclicos como ativadores de guanilato ciclase solúveis | |
| HRP20140206T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| ECSP16070327A (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| HRP20171041T1 (hr) | Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže | |
| MX2019008256A (es) | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. | |
| MX2019007053A (es) | Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas. | |
| PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| BR112021018238A2 (pt) | Derivados de azolopiridina macrocíclicos como moduladores de eed e prc2 | |
| MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| HRP20230362T1 (hr) | Kompozicije koje sadrže triciklične heterorociklične spojeve | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| CL2020000553A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso. | |
| GEP20207070B (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists |